Sign in
CompletedNo phase

Detecting Drugs of Abuse Via Exhaled Breath Samples Using Differential Mobility Spectrometry

Key facts

Who runs it
Mclean Hospital
Where
Belmont, United StatesSee the site
Trial code
Status
Completed
People taking part
32 people enrolled
Started
1 Aug 2021
Ended
15 Aug 2024
Type of study
Observational
Treatments tested
  • Marihuana
  • BID2 Instrument - breathalyzer
Record updated
2 May 2025

Who can take part

Age
21 years to 50 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Capable of understanding and complying with the protocol
  • In good physical and mental health (normal physical exam, ECG, blood and urine chemistries
  • Absence of history or laboratory evidence of diabetes)
  • Body Mass Index between 18-30,
  • Inclusive Age 21-50 years (age will be verified by driver's license or other valid form of identification)
  • Have a stable living situation with current postal address

Who cannot take part

  • Concurrent diagnosis of Axis 1 disorder be maintained on an antipsychotic or antidepressant medication
  • Meets criteria for current alcohol or substance use disorders (Past alcohol or substance use disorders greater than 3 years ago is acceptable)
  • Taking prescription medications except certain short-term anti-fungal agents and some topical creams for dermal condition
  • History of major head trauma resulting in cognitive impairment or history of seizure disorder
  • Has active hepatitis and/or aspartate aminotransferase (AST), alanine aminotransferase (ALT)> 3x the upper limit of normal
  • Heavy alcohol drinkers (greater than 15 drinks per week)
  • Tobacco use greater than 5 cigarettes per day
  • Heavy caffeine use (greater than 500 mg on a regular daily basis)
  • For female participants, a positive pregnancy test

Where in United States

  • McLean HospitalBelmont, United States

About the trial

What the trial wants to find out

This Phase II STTR program consists of two major goals within the overarching goal of developing and validating a proprietary device (BID2) for marijuana and opioid detection in breath samples.

The group in the trial

  • Exhaled Breath Samples

    Quantitative detection of marijuana, morphine or fentanyl through exhaled breath

    Treatment: Marihuana and BID2 Instrument - breathalyzer

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
2 May 2025